Navigation Links
Real Time Genomics Launches Two New Products in Human Disease Research
Date:8/27/2013

San Francisco, California (PRWEB) August 27, 2013

Real Time Genomics, Inc., the genome analytics company, today announced the commercial introduction of its rtgSingleton™ product for the genomic analysis of individual samples, and the Beta release of its rtgPopulation™ product for case-control and cohort applications. The singleton product is designed to analyze panels, exomes or genomes on a case-by-case basis. The population product is designed to work under two distinct scenarios: (1) analyze large sample numbers simultaneously; and (2) leverage prior information obtained from a population dataset to improve outcomes in the analysis of population subsets. The two new products complement the company’s rtgFamily™ offering, which is the industry leader in genomic analysis for early childhood disease.

The company also announced an exciting new milestone for its pedigree-aware rtgFamily product. RTG’s R&D team has validated that the product can reduce the cost of sequencing trios (both parents and a child) by at least 33 percent with no tradeoff in accuracy by enabling the parents of an offspring to be sequenced at half the typical coverage and still identify recessive, compound heterozygotes, and autosomal dominant disease variants. Results from this reduced-sequencing workflow showed greater than 99.9 percent concordance between variants identified in the proband when compared to sequencing the trio at full-coverage. In addition, the reduced coverage workflow maintained RTG’s sixty-fold reduction in Mendelian inconsistent errors for the proband as compared to analyzing that individual without parental genomes. To expand this validation across a wide array of samples, the company kicked off the ‘3-for-2 Challenge’ whereby a limited number of customers can submit trio data to RTG to be analyzed at both full and reduced-parental coverage. Results will be delivered free of charge directly to customers at this year’s ASHG conference in Boston, MA. Details about the cost reduction capabilities of rtgFamily and the ‘3-for-2 Challenge’ can be found on the company’s website.

“The ability to deliver improved results at a fraction of the cost could advance early childhood disease outcomes by enabling more family sequencing,” said Jason Blue-Smith, Head of Product for Real Time Genomics. “Capitalizing on the accuracy benefits of using parental genotypes, medical researchers have now successfully integrated our pedigree-aware product into their clinical workflows. The addition of singleton and population products to RTG’s human genetics portfolio allows biomedical researchers to run different experiment types through a uniform core analytical technology.”

About Real Time Genomics, Inc.
Real Time Genomics (http://www.realtimegenomics.com) has a passion for genomics. The company offers software tools and applications for the extraction of unique value from genomic data. Its competency lies in applying the combination of its patented core technology and deep computational expertise in algorithms to solve problems in next generation genomic analysis. Real Time Genomics is a private San Francisco based company backed by investment from Catamount Ventures, Lightspeed Venture Partners, and GeneValue Ltd.

Read the full story at http://www.prweb.com/releases/2013/8/prweb11060076.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Synthetic Genomics Inc. Hires Industry Leader George E. Stagnitti to Head Food and Nutritional Products Development Program
2. New England Biolabs Signs Agreement with Synthetic Genomics Inc. to Launch Gibson Assembly™ Master Mix for Molecular and Synthetic Biology Applications
3. Rubicon Genomics and Agendia Sign Agreement for Use of TransPLEX® Whole Genome RNA Amplification Technology With Symphony™ Cancer Diagnostics
4. Synthetic Genomics Inc. Purchases 81 Acre Site in South California Desert for Scale up and Testing of Innovative Algae Strains
5. Rosetta Genomics Pays Off Secured Loan and Reclaims Unencumbered Rights to All Assets
6. First Plant Genomics Yield Technology Progresses
7. Rosetta Genomics Announces Closing of Public Offering of 5.5 Million Ordinary Shares
8. Rosetta Genomics Receives 2012 North American Entrepreneurial Company of the Year Award by Frost & Sullivan
9. Rosetta Genomics Expands Management Team, Laboratory Capacities and Commercial Operations
10. Epigenomics, Present and Future Applications for Pharmaceuticals and Diagnostics: Twease.org
11. Synthetic Genomics Inc. Purchases Patent Portfolio from Febit Holding GmbH
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , Dec. 2, 2016 Amgen (NASDAQ: ... ) today announced the submission of a Marketing Authorization Application ... a biosimilar candidate to Avastin ® (bevacizumab). The companies ... to the EMA. "The submission of ABP ... seeks to expand our oncology portfolio," said Sean E. ...
(Date:12/2/2016)... ... , ... ACEA Biosciences, Inc. announced today that it will be presenting updated ... World Conference on Lung Cancer 2016, taking place in Vienna, Austria December 3rd-8th. ... for AC0010 in patients with advanced non-small cell lung cancer harboring the EGFR T790M ...
(Date:12/2/2016)... ... December 01, 2016 , ... ... (CSS) and the popularity of US Single Day Events (SDE) to organize a ... Summer 2018, in Raleigh, NC. Topics of the pharmaceutical and life sciences industry ...
(Date:12/2/2016)... IL (PRWEB) , ... December 01, 2016 , ... ... to congratulate long-term client Nanowear on their recent FDA Class II 510(k) clearance ... cleared a significant hurdle in commercializing remote cardiac monitoring devices that rely on ...
Breaking Biology Technology:
(Date:11/22/2016)... Minn. , Nov. 22, 2016   MedNet ... supports the entire spectrum of clinical research, is pleased ... Medical LiveWire Healthcare and Life Sciences Awards ... award caps off an unprecedented year of recognition and ... trials for over 15 years. iMedNet ...
(Date:11/17/2016)... , Nov. 17, 2016 Global Market Watch: ... Public Biobanks (Disease-Based Banks, Population-Based Banks and Academics) market is ... analysis for Private Biobanks shows the highest Compounded Annual Growth ... region during the analysis period 2014-2020. ... CAGR of 9.95% followed by Europe ...
(Date:11/15/2016)... , Nov. 15, 2016  Synthetic Biologics, ... developing therapeutics focused on the gut microbiome, today ... of 25,000,000 shares of its common stock and ... stock at a price to the public of ... to Synthetic Biologics from the offering, excluding the ...
Breaking Biology News(10 mins):